STOCK TITAN
  1. Home
  2. News
  3. NYXH

Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.

Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.

Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.

The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.

Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.

Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.

Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.

News

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Rhea-AI Summary
Nyxoah to participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference to showcase innovative solutions for Obstructive Sleep Apnea treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
conferences
-
News

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Rhea-AI Summary
Nyxoah SA (NYXH) will release its financial results for the fourth quarter and financial year 2023 on March 5, 2024. The Company, focused on treating Obstructive Sleep Apnea, will host a conference call to discuss the results. Investors can access the webcast through the Nyxoah website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
earnings
-
News

Nyxoah Announces 2024 Strategic Priorities

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced its strategic priorities for 2024, including completing patient follow-up in the DREAM U.S. pivotal study, filing the final module in the modular PMA submission, accelerating investments in the U.S. commercial organization, and increasing hypoglossal nerve stimulation market penetration and Genio market share in Europe. The company also emphasized its mission to improve the lives of OSA patients and highlighted the upcoming reporting of DREAM results as a significant milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
News

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces preliminary unaudited results for the fourth quarter and full year 2023, with anticipated revenue of approximately €1.8 million for Q4, a 40% increase over Q4 2022, and €4.3 million for the full year 2023, a 41% increase over 2022. The company also ended the year with 48 active German accounts. CEO Olivier Taelman expressed excitement for the strong sales growth, attributing it to the demand for Genio and streamlined patient referral pathways. The company anticipates an exciting 2024 with the upcoming DREAM US pivotal trial data, FDA approval filing, US market entry preparations, and contributions from the ResMed commercial partnership in Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
earnings
-
News

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced positive results in treating complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023, showed an average AHI decrease of 73%. The results demonstrated significant improvements in AHI and ESS, with no implant-related adverse events reported. The company's CEO, Olivier Taelman, expressed excitement about the potential FDA approval and the opportunity to bring Genio to CCC patients in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
News

Publication Relating to a Transparency Notification

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from Deerfield Partners, L.P. indicating that they crossed the 3% threshold on November 30, 2023, holding 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
News

Nyxoah Strengthens its Executive Leadership Team

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. With over 25 years of experience in the healthcare industry, Francis will lead Nyxoah’s Global Regulatory and Quality departments. His previous roles at Medtronic, Philips, and other companies make him a valuable addition to Nyxoah during a crucial period, with the DREAM U.S. pivotal study data expected in early 2024 and FDA approval anticipated by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
management
-
News

Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Nyxoah SA (NYXH) to Participate in Piper Sandler 35th Annual Healthcare Conference. Olivier Taelman, CEO, to Speak at Fireside Chat on November 29, 2023, at 2:30pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
News

Nyxoah Reports Third Quarter 2023 Financial and Operating Results

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported financial and operating results for Q3 2023, including a commercial partnership with ResMed Germany to increase OSA awareness and therapy penetration. The company ended the quarter with €1.0 million in sales, €72.5 million in cash, and accelerated U.S. pre-commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.1%
Tags
earnings
News

Nyxoah to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) to Participate in Jefferies London Healthcare Conference, CEO to Deliver Corporate Update on November 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
conferences

FAQ

What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?

The current stock price of Nyxoah SA Ordinary Shares (NYXH) is $8.01 as of December 20, 2024.

What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?

The market cap of Nyxoah SA Ordinary Shares (NYXH) is approximately 298.7M.

What is Nyxoah SA's core business?

Nyxoah SA focuses on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

What is the Genio system?

The Genio system is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe Obstructive Sleep Apnea (OSA).

What conditions does Nyxoah's Genio system address?

The Genio system targets Obstructive Sleep Apnea (OSA), which is associated with increased mortality risk and comorbidities like cardiovascular diseases, depression, and stroke.

How does Nyxoah update its stakeholders?

Nyxoah ensures transparency by continually updating stakeholders with the latest company news, performance information, and strategic initiatives.

Where is Nyxoah SA headquartered?

Nyxoah SA is headquartered in Belgium, with its innovative solutions reaching markets worldwide.

What makes the Genio system unique?

The Genio system is unique due to its bilateral stimulation approach, providing an effective and non-invasive treatment for OSA by opening the airway during sleep.

What recent achievements has Nyxoah accomplished?

Nyxoah has made significant strides in clinical trials, market expansion, and strategic partnerships, highlighting its growth potential and commitment to innovation.

What is OSA?

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to breathing interruptions.

Why invest in Nyxoah SA?

Nyxoah SA offers innovative solutions for OSA, a condition with significant health risks. The company's continuous advancements, strategic partnerships, and commitment to innovation make it a promising investment opportunity.

What are Nyxoah's future plans?

Nyxoah aims to expand its global presence, enhance its product offerings, and continue investing in research and development to bring effective solutions for sleep-disordered breathing conditions.

Stock NYXH logo
Nyxoah SA Ordinary Shares

Nasdaq:NYXH

NYXH Rankings

#3533 Ranked by Market Cap
N/A Ranked by Dividends

NYXH Stock Data

298.67M
22.46M
41.74%
35.37%
0.12%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert